Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioadaptives (BDPT) Total Current Liabilities (2019 - 2025)

Bioadaptives' Total Current Liabilities history spans 7 years, with the latest figure at $2.4 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $2.4 million for Q4 2025, up 36.51% from a year ago — trailing twelve months through Dec 2025 was $2.4 million (up 36.51% YoY), and the annual figure for FY2025 was $2.4 million, up 36.51%.
  • Total Current Liabilities for Q4 2025 was $2.4 million at Bioadaptives, up from $1.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $2.4 million in Q4 2025 to a low of $1.2 million in Q1 2021.
  • The 5-year median for Total Current Liabilities is $1.6 million (2022), against an average of $1.6 million.
  • Peak annual rise in Total Current Liabilities hit 36.51% in 2025, while the deepest fall reached 27.07% in 2025.
  • Year by year, Total Current Liabilities stood at $1.2 million in 2021, then grew by 19.91% to $1.5 million in 2022, then increased by 17.59% to $1.8 million in 2023, then dropped by 1.42% to $1.7 million in 2024, then soared by 36.51% to $2.4 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $2.4 million, $1.6 million, and $1.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.